These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

71 related articles for article (PubMed ID: 7743541)

  • 1. Government intervention in cardiovascular disease--help or hindrance? A Swedish viewpoint.
    Jönsson B
    Cardiology; 1994; 85 Suppl 1():90-5. PubMed ID: 7743541
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Evaluating a collaborative smoking cessation intervention in primary care (ENTER): study protocol for a cluster-randomized controlled trial.
    Härter M; Bartsch AL; Egger N; König HH; Kriston L; Schulz H; Tiemann M; Brütt AL; Buchholz A
    Trials; 2015 Oct; 16():447. PubMed ID: 26452466
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Government intervention in cardiovascular disease--help or hindrance? A clinician's viewpoint.
    Campbell RW
    Cardiology; 1994; 85 Suppl 1():113-7. PubMed ID: 7743528
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Government intervention in cardiovascular disease--help or hindrance? The pharmaceutical industry viewpoint.
    Marlow HF
    Cardiology; 1994; 85 Suppl 1():102-12. PubMed ID: 7743527
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cost-effectiveness analysis of adding pharmacists to primary care teams to reduce cardiovascular risk in patients with Type 2 diabetes: results from a randomized controlled trial.
    Simpson SH; Lier DA; Majumdar SR; Tsuyuki RT; Lewanczuk RZ; Spooner R; Johnson JA
    Diabet Med; 2015 Jul; 32(7):899-906. PubMed ID: 25594919
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of a pharmacist-managed hypertension program on health system costs: an evaluation of the Study of Cardiovascular Risk Intervention by Pharmacists-Hypertension (SCRIP-HTN).
    Houle SK; Chuck AW; McAlister FA; Tsuyuki RT
    Pharmacotherapy; 2012 Jun; 32(6):527-37. PubMed ID: 22552863
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A cost-effectiveness study of person-centered integrated heart failure and palliative home care: Based on a randomized controlled trial.
    Sahlen KG; Boman K; Brännström M
    Palliat Med; 2016 Mar; 30(3):296-302. PubMed ID: 26603186
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The economic costs for the control of cardiovascular risk: an overview.
    Leone A
    Curr Pharm Des; 2013; 19(13):2447-53. PubMed ID: 23173594
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Evaluating the costs and effectiveness of cardiovascular therapies: who cares about economic analyses?
    Califf RM
    Stat Med; 2002 Oct; 21(19):2889-97. PubMed ID: 12325105
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Government intervention in cardiovascular disease--help or hindrance? The US viewpoint.
    Bloom BS
    Cardiology; 1994; 85 Suppl 1():96-101. PubMed ID: 7743542
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A Markov model of the cost-effectiveness of pharmacist care for diabetes in prevention of cardiovascular diseases: evidence from Kaiser Permanente Northern California.
    Yu J; Shah BM; Ip EJ; Chan J
    J Manag Care Pharm; 2013 Mar; 19(2):102-14. PubMed ID: 23461426
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cost-effectiveness of interventions to prevent cardiovascular disease in Australia's indigenous population.
    Ong KS; Carter R; Vos T; Kelaher M; Anderson I
    Heart Lung Circ; 2014 May; 23(5):414-21. PubMed ID: 24252448
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cost-effectiveness of enhancing adherence to therapy with statins in the setting of primary cardiovascular prevention. Evidence from an empirical approach based on administrative databases.
    Corrao G; Scotti L; Zambon A; Baio G; Nicotra F; Conti V; Capri S; Tragni E; Merlino L; Catapano AL; Mancia G
    Atherosclerosis; 2011 Aug; 217(2):479-85. PubMed ID: 21592477
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Morbidity, mortality and economic burden of renal impairment in cardiac intensive care.
    Chew DP; Astley C; Molloy D; Vaile J; De Pasquale CG; Aylward P
    Intern Med J; 2006 Mar; 36(3):185-92. PubMed ID: 16503954
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Economics of psychosocial factors in patients with cardiovascular disease.
    Rodwin BA; Spruill TM; Ladapo JA
    Prog Cardiovasc Dis; 2013; 55(6):563-73. PubMed ID: 23621966
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Economic evaluations on cardiovascular preventive interventions in Argentina.
    Colantonio LD; Martí SG; Rubinstein AL
    Expert Rev Pharmacoecon Outcomes Res; 2010 Aug; 10(4):465-73. PubMed ID: 20715922
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Evaluation of Pharmacists' Work in a Physician-Pharmacist Collaborative Model for the Management of Hypertension.
    Isetts BJ; Buffington DE; Carter BL; Smith M; Polgreen LA; James PA
    Pharmacotherapy; 2016 Apr; 36(4):374-84. PubMed ID: 26893135
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Increasing awareness and perception of heart failure in Europe and improving care--rationale and design of the SHAPE Study.
    Remme W; Boccanelli A; Cline C; Cohen-Solal A; Dietz R; Hobbs R; Keukelaar K; Sendon JL; Macarie C; McMurray J; Rauch B; Ruzyllo W; Zannad F;
    Cardiovasc Drugs Ther; 2004 Mar; 18(2):153-9. PubMed ID: 15162077
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Costs of the 'Hartslag Limburg' community heart health intervention.
    Ronckers ET; Groot W; Steenbakkers M; Ruland E; Ament A
    BMC Public Health; 2006 Mar; 6():51. PubMed ID: 16512909
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Economic burden and the cost-effectiveness of treatment of cardiovascular diseases in Africa.
    Gaziano TA
    Heart; 2008 Feb; 94(2):140-4. PubMed ID: 18195120
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.